With the launch of four adalimumab biosimilars into the European market in October 2018—Amgevita (Amgen), Imraldi (Biogen), Hulio (Mylan), and Hyrimoz (Sandoz)—competition within the already…
DRG Epidemiology's coverage of chronic low back pain (CLBP) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of CLBP for…
DRG Epidemiology's coverage of ACS comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of acute coronary…
Eli Lilly’s Olumiant is the second-in-class Jak inhibitor approved for rheumatoid arthritis (RA) in the United States. Its launch comes years after that of Pfizer’s Jak inhibitor, Xeljanz (…
DRG Epidemiology’s coverage of gastric cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of gastric …
DRG Epidemiology’s coverage of peripheral arterial disease (PAD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PAD for each…
As the term implies, levodopa-induced dyskinesia (LID) is a complication of chronic use of levodopa, the gold standard of Parkinson’s disease (PD) treatment. Surveyed neurologists estimate that…
DRG Epidemiology’s coverage neuropathic back pain(NBP) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of NBP…
The wet age-related macular degeneration (AMD) market in the United States is unique in that it is dominated by Genentech’s Avastin, an oncology drug that is used off-label to treat wet AMD,…
MARKET OUTLOOK Despite similarities between adult psoriasis and pediatric psoriasis, pediatric psoriasis presents a challenge for patients seeking effective long-term therapy. Thetreatments…
MARKET OUTLOOK Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key…
MARKET OUTLOOK Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are gaining traction in the COPD market, and both LAMAs and LABA/…
For the estimated 5 million people in the United States with AF, several treatment approaches are used, each with a wide range of pharmacological options. The established guidelines recommend the…
Most uveitis-related vision loss is the result of chronic inflammation of the posterior segment of the eye (i.e., intermediate, posterior, and panuveitis). Although noninfectious anterior uveitis…
DRG Epidemiology’s coverage of cystic fibrosis (CF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of CF for…